title: Original version Date:24/08/2016
text: |
  Original version Date:24/08/2016
  |
  bet | 349/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
  Original version Date:24/08/2016
  |
  Author: NMF Consensus Group/TC
  |
  Current Version number: 2
  |
  Current Version Date: 19/04/2018
  |
  Risk Rating: Low
  |
  Due for Review: 19/04/23
  |
  Approval by: DTC
  |
  Approval Date:
  |
  Meropenem |
  Revision Date : 11-12-2020
  |
  Approve : TC, KOH
  |
  Alert
  |
  The Antimicrobial Stewardship Team recommends this drug is listed under the following category: Restricted.
  Widespread use of carbapenems has been linked with increasing prevalence of infections caused by methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), multi-resistant Gram-negative organisms and Clostridium difficile.
  |
  Indication
  |
  Severe infections (e.g., sepsis or meningitis) caused by Gram-negative organisms resistant to other conventional antibiotics but susceptible to meropenem e.g., Extended Spectrum Beta Lactamase (ESBL)-producing organisms.
  Note: Meropenem is NOT active against many resistant Gram-positive organisms, such as MRSA and most Staphylococcus epidermidis. Vancomycin is first-line therapy for these. Meropenem does have activity against penicillin-susceptible Gram-positive organisms and most anaerobic organisms. For individual advice, discuss therapy with a microbiologist or infectious diseases physician.
  |
  Action
  |
  Meropenem is a carbapenem. It inhibits cell wall synthesis. (1)
  Meropenem is a better choice than imipenem for central nervous system infections. Meropenem attains a higher concentration in the cerebrospinal fluid particularly with inflamed meninges and has a lower incidence of seizures than imipenem.
  |
  Drug type
  |
  Carbapenem antibiotic.
  |
  Trade name
  |
  Meropenem APOTEX, Meropenem DBL, Meropenem GH, Meropenem Juno, Meropenem Kabi, Meropenem Sandoz, Merrem
  |
  Presentation
  |
  500 mg vial
  1000 mg vial
  |
  Dose
  |
  |
  |
  | |